Inhibition stat-1

Abstract

The present invention relates to inhibitors of the transcription factor STAT-1, their use as therapeutic means as well as their use for the prevention or therapy of cardio-vascular complications like restenosis after percutaneous angioplasty or stenosis of venous bypasses, the graft versus host reaction, the ischemia/refusion-related damage in the context of surgical interventions and organ transplantation respectively, immunological hypersensitivity reactions, in particular the allergic rhinitis, the drug and food allergies, in particular urticaria and celiac disease (sprue), contact eczema and the immune complex diseases, in particular alveolitis, arthritis, glomerulonephritis and allergic vasculitis, inflammatory chondro- and osteopathies, in particular arthrosis, gout, ostitis and osteomyelitis, polyneuritis as well as acute and subacute respectively, infection contingent and in particular post-infectious inflammatory diseases, in particular bronchitis, endocarditis, hepatitis, myocarditis, nephritis, pericarditis, peritonitis and pancreatitis, including the septic shock.

1 . A method for the prevention or therapy of a disease state associated with STAT-1 activity comprising administering to a subject in need thereof a double-stranded DNA-oligonucleotide, a single stranded antisense-oligonucleotide, an antisense-expression vector or a double-stranded RNA-interference-oligonucleotide that inhibits STAT-1 activity. 
     
     
         2 . The method according to  claim 1 , wherein the disease state is cardio-vascular complications like restenosis after percutaneous angioplasty or stenosis of venous bypasses, the graft versus host reaction, the ischemia/refusion-related damage in the context of surgical interventions and organ transplantation respectively, immunological hypersensitivity reactions, in particular the allergic rhinitis, the drug and food allergies, in particular urticaria and celiac disease (sprue), contact eczema and the immune complex diseases, in particular alveolitis, arthritis, glomerulonephritis and allergic vasculitis, inflammatory chondro- and osteopathies, in particular arthrosis, gout, ostitis and osteomyelitis, polyneuritis as well as acute and subacute respectively, infection contingent and in particular post-infectious inflammatory diseases, in particular bronchitis, endocarditis, hepatitis, myocarditis, nephritis, pericarditis, peritonitis or pancreatitis, including the septic shock. 
     
     
         3 . The method of  claim 1 , wherein said double-stranded DNA-oligonucleotide is administered. 
     
     
         4 . The method of  claim 1 , wherein said single stranded antisense-oligonucleotide is administered. 
     
     
         5 . The method of  claim 1 , wherein said antisense-expression vector is administered. 
     
     
         6 . The method of  claim 5 , wherein the vector is a plasmid vector. 
     
     
         7 . The method of  claim 1 , wherein said double-stranded RNA-interference-oligonucleotide is administered. 
     
     
         8 . The method of  claim 1 , wherein said double-stranded DNA-oligonucleotide, said single stranded antisense-oligonucleotide, said antisense-expression vector or said double-stranded RNA-interference-oligonucleotide is administered by injection, catheter, suppository, aerosol, trocar, projectile, pluronic gel or polymer. 
     
     
         9 . The method of  claim 1 , further comprising ex vivo administration of said double-stranded DNA-oligonucleotide, said single stranded antisense-oligonucleotide, said antisense-expression vector or said double-stranded RNA-interference-oligonucleotide. 
     
     
         10 . The method of  claim 1 , wherein administering brings said double-stranded DNA-oligonucleotide, said a single stranded antisense-oligonucleotide, said antisense-expression vector or said double-stranded RNA-interference-oligonucleotide into contact with an endothelial cell, an epithelial cell, a leukocyte, a smooth muscle cell, a keratinocyte or a fibroblast.